Gymnestrogenin has a dual LXRα±/α2 antagonistic profile.

The study disclosed for the first time that individual gymnemic acids are potent and selective antagonists for the β isoform of LXR. Indeed the above activity was shared by the most abundant aglycone gymnemagenin (10) whereas Gymnestrogenin (11) was endowed with a dual LXRα±/β antagonistic profile. Deep pharmacological investigation demonstrated that Gymnestrogenin, reducing the expression of SREBP1c and ABCA1 in vitro, is able to decrease lipid accumulation in HepG2 cells.

19942-02-0

C30H50O5

490.72

匙羹藤苷元;(3BETA,4ALPHA,16BETA,21BETA)-齐墩果-12-烯-3,16,21,23,28-五醇

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years